OP0222 THE INCIDENCE OF INTERSTITIAL LUNG DISEASE IN PSORIATIC ARTHRITIS COMPARED TO RHEUMATOID ARTHRITIS. DATA FROM OVER 89 000 BDMARD TREATMENT COURSES DERIVED FROM FIVE NORDIC REGISTERS

• Published in: Annals of the Rheumatic Diseases
• Main Authors: Aarrestad Provan, S., Michelsen, B., Ljung, L., Jonmundsson, T., Gudbjornsson, B., DI Giuseppe, D., Hetland, M. L., Reynisdóttir, G. B., Glintborg, B., Kristianslund, E., Relas, H., Aaltonen, K., Nordström, D., Kvien, T. K., Askling, J.
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMJ 2021
• Subjects: General Biochemistry, Genetics and Molecular Biology; Immunology; Immunology and Allergy; Rheumatology; Norway; Orion; Michelsen; Lotta; Kalle; Iceland
• Online Access: http://dx.doi.org/10.1136/annrheumdis-2021-eular.2955; https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2021-eular.2955

Background: Interstitial lung disease (ILD) is an established extra-articular manifestation of rheumatoid arthritis (RA). Few studies have investigated the prevalence of ILD in patients with psoriatic arthritis (PsA). Methotrexate (MTX) is frequently used in the treatment of both RA and PsA and has...